Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
ID: 357019Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357019

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-325-Full-Announcement.html
    PAR-24-325.html
    The Department of Health and Human Services announces a funding opportunity titled "Bioengineering Partnerships with Industry," aimed at accelerating the development and adoption of innovative bioengineering tools and technologies that address critical biomedical challenges. This program encourages collaborative partnerships between academic researchers and industry stakeholders to create multidisciplinary teams focused on engineering solutions with a clear timeline and measurable goals within a 5-10 year timeframe. Key eligible applicants include higher education institutions, nonprofits, and for-profit organizations, particularly those that emphasize diversity and inclusion in research. The program requires a Leadership Plan detailing the roles and contributions of each team member, especially the industrial partner. Applications will undergo rigorous peer review based on factors such as significance, innovation, approach, and the expertise of investigators. The anticipated funding supports cooperative agreements, with no specific budget limits, subject to project needs, and follows strict compliance with NIH policies. The initiative recognizes the essential role of industry in transforming technologies into robust solutions that meet the needs of the medical community and ultimately enhance patient care.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) under the R01 Clinical Trial Optional program, aimed at fostering collaborations between life and physical sciences to address biomedical challenges. The grants encourage multidisciplinary bioengineering approaches that integrate and accelerate the adoption of innovative tools and methods for research or clinical problems in basic, translational, or clinical science. This funding opportunity is particularly significant for small teams looking to enhance understanding and solve issues in biological and clinical sciences. Interested applicants can reach out to Dr. Miguel R. Ossandon at ossandom@mail.nih.gov or by phone at 240-276-5714, with an estimated award date of December 1, 2026, and a closing date for applications on February 5, 2026. The program anticipates awarding approximately 50 grants, with no cost-sharing or matching requirements.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial entities to develop innovative solutions for critical health challenges, particularly in the fields of cancer and eye health. The program encourages interdisciplinary research teams to enhance and validate technologies that improve diagnostic methods and treatment capabilities, ultimately supporting better health outcomes for diverse populations. The funding amount is capped at $499,000 annually, with a maximum project duration of five years. Initial submissions are due by January 5, 2025, and interested applicants can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    Opportunities for Collaborative Research at the NIH Clinical Center
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Opportunities for Collaborative Research at the NIH Clinical Center," aimed at supporting collaborative translational research projects that enhance the application of basic biological discoveries to clinical settings. This program encourages partnerships between NIH intramural investigators and extramural researchers to accelerate patient-centric translational research, focusing on understanding disease processes and developing new therapeutic interventions, diagnostics, or prevention strategies. Interested small businesses can apply for this cooperative agreement, with no cost-sharing requirement, and should note that the estimated synopsis post date is September 1, 2025, with a closing date of December 12, 2025. For further inquiries, applicants can contact Dr. David J. Eckstein at 301-496-4121 or via email at ClinicalCtrPartner@mail.nih.gov.
    PRIMED-AI: Academic-Industrial Partnerships (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "PRIMED-AI: Academic-Industrial Partnerships (UG3/UH3 Clinical Trial Optional)" aimed at developing innovative AI-based tools that integrate clinical imaging with multimodal health data to enhance personalized medicine for patients with chronic conditions. This initiative will focus on fostering collaborations between academic institutions and industry partners to improve data integration and interoperability, followed by algorithm development and performance testing in a subsequent phase. The estimated total program funding is $2.9 million, with applications expected to open in July 2025 and close in November 2025, while the anticipated award date is September 2026. Interested parties can reach out to Dr. Sahana N. Kukke at ODPRIMED-AI@od.nih.gov or by phone at 301-402-3756 for further information.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.